Research chemicals sold online without this designation have no verified purity or concentration, and results from them cannot be meaningfully compared to a supervised clinical protocol
The route used in the majority of preclinical work and in most human case series

CJC-1295 (NO DAC) + Ipamorelin Blend Peptide Research Applications & Key Findings Growth Hormone Secretion Research Pituitary Function Studies Extensive research has examined the growth hormone secretagogue properties of the CJC-1295 + Ipamorelin combination across multiple species: Dose-dependent GH release demonstrated in rat anterior pituitary cell cultures with picomolar to micromolar peptide concentrations 2- to 10-fold increases in plasma growth hormone levels sustained for 6 days in human subjects following single CJC-1295 dose Preserved pulsatile secretion with ipamorelin addition, preventing continuous non-physiological stimulation Selective action on growth hormone release without affecting prolactin, ACTH, cortisol, FSH, or TSH levels Human trials with healthy subjects aged 21-61 years demonstrated sustained, dose-dependent increases in growth hormone and IGF-1 levels that were safe and well-tolerated at doses of 30-60 mcg/kg

The tissue usually recovers, but continued injection into affected areas makes it worse
Numeric data are expressed as the mean standard deviation (SD) and were analyzed by one-way ANOVA followed by LSD test
Lyophilized preparations are generally reconstituted using bacteriostatic water and refrigerated between 2 and 8C after mixing